Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:IMNP NASDAQ:OKUR NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$11.29-4.9%$13.39$5.70▼$22.90$22.20M0.9543,711 shs26,107 shsIMNPImmune Pharmaceuticals$0.00$0.00▼$0.48$8.14MN/A12.29 million shsN/AOKUROnKure Therapeutics$2.33-2.1%$2.44$1.70▼$20.00$31.48M0.41107,045 shs131,662 shsSCYXSCYNEXIS$0.73-2.0%$0.80$0.66▼$2.28$28.29M1.57167,060 shs147,473 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-12.62%-15.68%-32.60%+1,128,999,900.00%IMNPImmune Pharmaceuticals0.00%0.00%0.00%0.00%0.00%OKUROnKure Therapeutics0.00%-6.80%-3.72%-19.38%+232,999,900.00%SCYXSCYNEXIS0.00%+3.13%-2.62%-19.83%-66.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVKDCadrenal Therapeutics2.2014 of 5 stars3.53.00.00.00.61.70.6IMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics2.654 of 5 stars3.70.00.00.00.62.51.3SCYXSCYNEXIS0.3524 of 5 stars0.03.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 3.00Buy$32.00183.44% UpsideIMNPImmune Pharmaceuticals 0.00N/AN/AN/AOKUROnKure Therapeutics 3.33Buy$32.331,287.70% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMNP, OKUR, SCYX, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/ASCYXSCYNEXIS$3.75M7.54N/AN/A$1.45 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)IMNPImmune PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics-$52.67M-$5.26N/AN/AN/AN/A-49.13%-45.72%8/12/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.56N/A14.50N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)Latest IMNP, OKUR, SCYX, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SCYXSCYNEXIS-$0.23N/AN/AN/AN/AN/A8/12/2025N/AOKUROnKure Therapeutics-$1.25N/AN/AN/AN/AN/A8/6/2025Q2 2025CVKDCadrenal Therapeutics-$1.60N/AN/AN/AN/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A4.324.32IMNPImmune PharmaceuticalsN/AN/AN/AOKUROnKure TherapeuticsN/A11.1811.17SCYXSCYNEXISN/A5.835.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%IMNPImmune Pharmaceuticals1.43%OKUROnKure Therapeutics90.98%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics48.62%IMNPImmune Pharmaceuticals3.85%OKUROnKure Therapeutics2.30%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionableIMNPImmune PharmaceuticalsN/A49.31 millionN/ANot OptionableOKUROnKure TherapeuticsN/A13.51 million13.20 millionN/ASCYXSCYNEXIS6039.02 million37.12 millionOptionableIMNP, OKUR, SCYX, and CVKD HeadlinesRecent News About These CompaniesSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30, 2025 | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 28, 2025 | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28, 2025 | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comSCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study RestartMarch 12, 2025 | quiverquant.comQSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comFederated Hermes, Inc. Expands Stake in SCYNEXIS IncOctober 7, 2024 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024October 3, 2024 | globenewswire.comSCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 SharesSeptember 17, 2024 | insidertrades.comSCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNP, OKUR, SCYX, and CVKD Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$11.29 -0.58 (-4.89%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.24 -0.05 (-0.44%) As of 07/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Immune Pharmaceuticals NASDAQ:IMNPImmune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.OnKure Therapeutics NASDAQ:OKUR$2.33 -0.05 (-2.10%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.38 +0.05 (+1.97%) As of 07/18/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.SCYNEXIS NASDAQ:SCYX$0.72 -0.02 (-2.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.73 +0.01 (+1.10%) As of 07/18/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
